GreenLight Biosciences Holdings (GRNA)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
GreenLight Biosciences Holdings (GRNA) with AI Score 57/100 (Hold). GreenLight Biosciences Holdings is a biotechnology company focused on developing RNA-based solutions for human health and agriculture. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 18, 2026GreenLight Biosciences Holdings (GRNA) Healthcare & Pipeline Overview
GreenLight Biosciences Holdings is a biotechnology firm specializing in RNA-based solutions for both human health and agricultural applications, offering mRNA vaccines and crop protection products. With a focus on sustainability and innovation, the company operates in a competitive landscape, marked by significant growth potential and inherent regulatory complexities.
Investment Thesis
GreenLight Biosciences Holdings presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's RNA-based platform offers potential for significant growth in both human health and agriculture. Key value drivers include successful development and commercialization of its mRNA vaccines and therapeutics, as well as its agricultural RNA products. The company's gross margin is currently 100.0%. Upcoming catalysts include potential regulatory approvals for its pipeline products and strategic partnerships to expand its market reach. However, the company's negative P/E ratio of -0.24 and a substantial negative profit margin of -2616.8% highlight the financial challenges and risks associated with investing in early-stage biotechnology companies. Investors should closely monitor the company's cash burn rate, regulatory milestones, and competitive landscape.
Based on FMP financials and quantitative analysis
Key Highlights
- Market capitalization of $0.05 billion, indicating a small-cap company with potential for growth but also higher volatility.
- Gross margin of 100.0%, reflecting the company's ability to efficiently produce its RNA-based products.
- Negative P/E ratio of -0.24, suggesting the company is currently not profitable.
- Profit margin of -2616.8%, highlighting significant expenses relative to revenue.
- Beta of 1.44, indicating higher volatility compared to the overall market.
Competitors & Peers
Strengths
- Proprietary RNA technology platform.
- Innovative and sustainable product offerings.
- Potential for high growth in both human health and agriculture.
- Experienced management team.
Weaknesses
- Negative profitability and high operating expenses.
- Reliance on regulatory approvals.
- Limited commercialized products.
- Small market capitalization.
Catalysts
- Upcoming: Regulatory approvals for mRNA vaccine candidates.
- Upcoming: Positive results from clinical trials of RNA-based therapeutics.
- Ongoing: Expansion of strategic partnerships and collaborations.
- Ongoing: Advancement of agricultural RNA product development.
Risks
- Potential: Clinical trial failures or delays.
- Potential: Regulatory hurdles and rejection of product approvals.
- Ongoing: Intense competition from established companies.
- Ongoing: Financial risks associated with high operating expenses and negative profitability.
Growth Opportunities
- Expansion of mRNA Vaccine Pipeline: GreenLight Biosciences has the opportunity to expand its mRNA vaccine pipeline to address a wider range of infectious diseases. The global vaccine market is projected to reach $100 billion by 2025, driven by increased awareness of preventative healthcare and advancements in vaccine technology. Successful development and commercialization of new mRNA vaccines could generate significant revenue streams for the company. The timeline for this growth opportunity depends on clinical trial outcomes and regulatory approvals.
- Agricultural RNA Products for Crop Protection: The company can further develop and commercialize its agricultural RNA products to protect crops from pests and diseases. The market for crop protection products is estimated at $70 billion annually, with increasing demand for sustainable and environmentally friendly solutions. GreenLight Biosciences's RNA-based products offer a targeted and biodegradable alternative to traditional chemical pesticides, providing a competitive advantage. The timeline for this growth opportunity depends on field trial results and regulatory approvals.
- Strategic Partnerships and Collaborations: Forming strategic partnerships and collaborations with established pharmaceutical companies and agricultural firms can accelerate the development and commercialization of GreenLight Biosciences's products. These partnerships can provide access to funding, expertise, and distribution networks, enhancing the company's market reach and competitive position. The timeline for this growth opportunity depends on the negotiation and execution of partnership agreements.
- Geographic Expansion into Emerging Markets: Expanding into emerging markets, such as Asia and Latin America, presents a significant growth opportunity for GreenLight Biosciences. These markets have a growing demand for innovative healthcare and agricultural solutions, driven by increasing populations and rising incomes. The timeline for this growth opportunity depends on market entry strategies and regulatory approvals in each target country.
- Development of RNA-based Therapeutics: GreenLight Biosciences can leverage its RNA platform to develop novel therapeutics for various diseases, including cancer and genetic disorders. The market for RNA-based therapeutics is projected to reach $25 billion by 2028, driven by advancements in RNA technology and increasing investment in drug development. Successful development and commercialization of new RNA-based therapeutics could generate substantial revenue streams for the company. The timeline for this growth opportunity depends on clinical trial outcomes and regulatory approvals.
Opportunities
- Expansion of mRNA vaccine pipeline.
- Development of RNA-based therapeutics.
- Strategic partnerships and collaborations.
- Geographic expansion into emerging markets.
Threats
- Intense competition from established pharmaceutical and biotechnology companies.
- Regulatory hurdles and clinical trial risks.
- Technological advancements by competitors.
- Economic downturns and market volatility.
Competitive Advantages
- Proprietary RNA Technology Platform: GreenLight Biosciences's proprietary RNA technology platform provides a competitive advantage by enabling the rapid and efficient development of RNA-based products.
- Intellectual Property Portfolio: The company's intellectual property portfolio, including patents and trade secrets, protects its technology and products from competition.
- First-Mover Advantage: GreenLight Biosciences has a first-mover advantage in certain segments of the RNA-based solutions market, particularly in agricultural applications.
- Strategic Partnerships: Strategic partnerships with established companies provide access to funding, expertise, and distribution networks.
About GRNA
Founded in 2008 and headquartered in Medford, Massachusetts, GreenLight Biosciences Holdings is a biotechnology company dedicated to developing and commercializing RNA-based solutions. The company operates at the intersection of human health and agriculture, leveraging its proprietary RNA platform to create innovative and sustainable products. In the human health sector, GreenLight Biosciences focuses on mRNA vaccines and therapeutics, aiming to address a range of diseases and improve patient outcomes. Its agricultural applications include RNA-based products designed to protect crops and honeybees, promoting sustainable farming practices and reducing reliance on traditional chemical pesticides. GreenLight Biosciences's mission is to provide effective and environmentally friendly alternatives to conventional methods in both healthcare and agriculture. The company's approach involves designing and manufacturing RNA molecules that can target specific biological processes, offering precise and efficient solutions. This technology has the potential to revolutionize various industries by providing sustainable and targeted interventions. The company's focus on RNA technology positions it within a rapidly evolving field, marked by increasing investment and scientific advancements. GreenLight Biosciences continues to invest in research and development to expand its product pipeline and address unmet needs in its target markets.
What They Do
- Manufactures RNA products for human health applications.
- Develops mRNA vaccines to combat infectious diseases.
- Creates mRNA therapeutics for treating various illnesses.
- Produces agricultural RNA products to protect crops.
- Offers RNA-based solutions for honeybee health.
- Focuses on sustainable and environmentally friendly alternatives.
- Utilizes a proprietary RNA platform for targeted interventions.
Business Model
- Develops and manufactures RNA-based products.
- Generates revenue through product sales to healthcare providers and agricultural businesses.
- Forms partnerships and collaborations for research and development.
- Seeks regulatory approvals for its products in various markets.
Industry Context
GreenLight Biosciences operates in the rapidly evolving biotechnology industry, characterized by intense competition and significant growth potential. The market for RNA-based therapeutics and agricultural solutions is expanding, driven by advancements in technology and increasing demand for sustainable products. The company competes with established pharmaceutical companies and other biotechnology firms, including ALVR, BLUE, ERYP, LIANY, and MGTA. The industry is subject to stringent regulatory requirements and faces challenges related to clinical trials, manufacturing, and market access. GreenLight Biosciences's success depends on its ability to innovate, secure regulatory approvals, and establish strategic partnerships.
Key Customers
- Healthcare providers and hospitals.
- Agricultural businesses and farmers.
- Government agencies and research institutions.
- Pharmaceutical companies (through partnerships).
Financials
Chart & Info
GreenLight Biosciences Holdings (GRNA) stock price: Price data unavailable
Latest News
-
Stocks That Hit 52-Week Lows On Thursday
benzinga · May 11, 2023
-
Stocks That Hit 52-Week Lows On Wednesday
benzinga · Feb 23, 2022
-
Stocks That Hit 52-Week Lows On Tuesday
benzinga · Feb 22, 2022
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for GRNA.
Price Targets
Wall Street price target analysis for GRNA.
MoonshotScore
What does this score mean?
The MoonshotScore rates GRNA's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Competitors & Peers
Leadership: Andrey Juan Zarur
CEO
Andrey Juan Zarur is the Chief Executive Officer of GreenLight Biosciences Holdings. His background includes extensive experience in the biotechnology and pharmaceutical industries. He has held leadership positions at various companies, focusing on strategic development, commercialization, and operational excellence. Zarur's expertise spans across multiple therapeutic areas and technological platforms, making him well-suited to lead GreenLight Biosciences in its mission to develop RNA-based solutions for human health and agriculture. He is responsible for managing the company's overall strategy and operations.
Track Record: Under Andrey Juan Zarur's leadership, GreenLight Biosciences Holdings has focused on advancing its RNA technology platform and expanding its product pipeline. Key milestones include securing partnerships, advancing clinical trials, and obtaining regulatory approvals for its products. Zarur has overseen the company's efforts to develop sustainable and innovative solutions for both healthcare and agriculture, positioning GreenLight Biosciences as a leader in the RNA-based solutions market.
Common Questions About GRNA
What does GreenLight Biosciences Holdings do?
GreenLight Biosciences Holdings is a biotechnology company that develops and manufactures RNA-based products for both human health and agricultural applications. In human health, they focus on mRNA vaccines and therapeutics, aiming to address various diseases. For agriculture, they create RNA-based solutions to protect crops and honeybees, promoting sustainable farming practices. The company leverages its proprietary RNA platform to offer targeted and environmentally friendly alternatives to conventional methods, positioning itself as an innovator in the biotechnology sector.
What do analysts say about GRNA stock?
Analyst coverage of GreenLight Biosciences Holdings (GRNA) is still emerging, reflecting its relatively early stage as a publicly traded company. Key valuation metrics, such as its negative P/E ratio, suggest that the company is currently not profitable, which is common for biotechnology firms investing heavily in research and development. Growth considerations center around the successful development and commercialization of its RNA-based products, as well as its ability to secure regulatory approvals and strategic partnerships. Investors should conduct their own due diligence and consider the risks and uncertainties associated with investing in early-stage biotechnology companies.
What are the main risks for GRNA?
GreenLight Biosciences Holdings faces several key risks inherent to the biotechnology industry. These include the potential for clinical trial failures or delays, regulatory hurdles and the risk of product approval rejection, and intense competition from established pharmaceutical and biotechnology companies. Additionally, the company faces financial risks associated with high operating expenses, negative profitability, and the need to raise additional capital to fund its research and development activities. These risks are compounded by the volatile nature of the biotechnology market and the potential for technological advancements by competitors.
How does GreenLight Biosciences Holdings navigate regulatory approval processes?
GreenLight Biosciences Holdings navigates regulatory approval processes by adhering to stringent guidelines set by regulatory agencies such as the FDA and EMA. The company conducts rigorous preclinical and clinical trials to demonstrate the safety and efficacy of its RNA-based products. GreenLight Biosciences also maintains a dedicated regulatory affairs team that works closely with regulatory agencies to ensure compliance with all applicable regulations. The company's strategy includes proactive communication with regulatory bodies, comprehensive documentation, and a commitment to transparency throughout the approval process.
What are the key growth opportunities for GRNA in healthcare?
GreenLight Biosciences Holdings has several key growth opportunities in the healthcare sector. These include expanding its mRNA vaccine pipeline to address a wider range of infectious diseases, developing novel RNA-based therapeutics for various diseases, and forming strategic partnerships with established pharmaceutical companies to accelerate the development and commercialization of its products. The company can also explore geographic expansion into emerging markets with unmet medical needs. Successful execution of these growth strategies could significantly enhance GreenLight Biosciences's market position and revenue streams.
What are the key factors to evaluate for GRNA?
GreenLight Biosciences Holdings (GRNA) currently holds an AI score of 57/100, indicating moderate score. Key strength: Proprietary RNA technology platform.. Primary risk to monitor: Potential: Clinical trial failures or delays.. This is not financial advice.
How frequently does GRNA data refresh on this page?
GRNA prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven GRNA's recent stock price performance?
Recent price movement in GreenLight Biosciences Holdings (GRNA) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Proprietary RNA technology platform.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- AI analysis is pending, which may provide additional insights.
- Financial data is based on the most recent available information.